Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2026

Description

Non-alcoholic steatohepatitis (NASH) is a severe form of fatty liver disease marked by liver inflammation, which can progress to cirrhosis and liver failure.

The main types of NASH treatments are solid and liquid forms. Solid forms are typically produced as crystalline solids and sold as tablets for oral use, due to their high purity and stability. Key products include vitamin E, pioglitazone, Ocaliva, elafibranor, selonsertib, cenicriviroc, and others, which are used to address conditions such as hypertension, heart disease, high blood lipids, type 2 diabetes, and obesity. These treatments are available through hospital pharmacies, retail pharmacies, and online providers, and are administered via oral and parenteral routes.

Tariffs have influenced the non-alcoholic steatohepatitis (NASH) market by affecting the import of active pharmaceutical ingredients (APIs) and advanced diagnostic equipment, leading to increased production costs. The impact is most significant on pharmaceutical formulations and diagnostic devices, especially in regions like North America and Europe that rely on global supply chains. While costs have increased, some domestic manufacturers benefit from tariffs by gaining a competitive advantage and encouraging local production of APIs and NASH-related therapies. Overall, tariffs are reshaping sourcing strategies and encouraging innovation to optimize cost-efficiency.

The non-alcoholic steatohepatitis (nash) market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis (nash) market statistics, including non-alcoholic steatohepatitis (nash) industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis (nash) market share, detailed non-alcoholic steatohepatitis (nash) market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (nash) industry. This non-alcoholic steatohepatitis (nash) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-alcoholic steatohepatitis (nash) market size has grown exponentially in recent years. It will grow from $6.06 billion in 2025 to $8.04 billion in 2026 at a compound annual growth rate (CAGR) of 32.7%. The growth in the historic period can be attributed to limited awareness about nash, lack of effective treatment options, reliance on lifestyle modifications, high prevalence of metabolic disorders, fragmented market landscape.

The non-alcoholic steatohepatitis (nash) market size is expected to see exponential growth in the next few years. It will grow to $24.32 billion in 2030 at a compound annual growth rate (CAGR) of 31.9%. The growth in the forecast period can be attributed to advancements in targeted therapies, increased healthcare expenditure, growing adoption of non-invasive diagnostics, expansion of pharmaceutical pipelines, rising collaborations for r&d. Major trends in the forecast period include rising prevalence of obesity and type 2 diabetes, development of non-invasive diagnostic tools, increasing research in liver fibrosis therapies, growth in personalized and targeted drug treatments, expansion of hospital and retail pharmacy networks.

The rising prevalence of obesity is driving demand in the non-alcoholic steatohepatitis (NASH) market. Obesity is defined as an abnormal or excessive accumulation of body fat that poses a health risk and is higher than what is considered healthy or normal for a person of a given height. As non-alcoholic fatty liver disease becomes increasingly common due to the obesity epidemic, NASH is projected to become a leading cause of severe liver disease in the coming decades, fueling demand for NASH treatments and related drugs. For example, in May 2025, according to the UK Government Digital Service, during 2023-2024, the prevalence of overweight (including obesity) in adults was higher among men (69.7%) than women (59.2%), while adult obesity rates were higher among women (26.9%) than men (26.2%). This trend underscores that rising obesity rates are expected to drive growth in the NASH market.

Key companies in the NASH market are focusing on the development of thyroid hormone receptor-beta (THR-beta) agonists to enhance liver metabolism, reduce liver fat accumulation, and improve liver function. THR-beta agonists are compounds that selectively activate the thyroid hormone receptor-beta subtype, which plays a crucial role in regulating metabolism, growth, and development. For instance, in March 2024, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom), a THR-beta agonist, as the first treatment for adults with noncirrhotic NASH and moderate to advanced liver fibrosis. By selectively targeting the THR-beta receptor, Rezdiffra regulates lipid metabolism, reducing intrahepatic triglycerides and overall liver fat accumulation.

In April 2024, Novo Nordisk A/S, a Denmark-based global healthcare company, entered research collaborations with Omega Therapeutics and Cellarity to explore novel treatments for cardiometabolic diseases. The partnerships aim to accelerate the discovery and development of innovative therapies targeting metabolic and cardiovascular conditions, improving patient outcomes while driving growth and innovation in the cardiometabolic disease sector. Omega Therapeutics is a US-based biotechnology company specializing in gene control therapeutics, and Cellarity is a US-based biotech firm focused on cell reprogramming-based drug discovery.

Major companies operating in the non-alcoholic steatohepatitis (nash) market are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2025. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-alcoholic steatohepatitis (nash) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Alcoholic Steatohepatitis (NASH) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses non-alcoholic steatohepatitis (nash) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis (nash) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-alcoholic steatohepatitis (nash) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Dosage Form: Solid; Liquid
2) By Product: Vitamin E and Pioglitazone; Ocaliva; Elafibranor; Selonsertib and Cenicriviroc; Other Products
3) By Disease Cause: Hypertension; Heart Disease; High Blood Lipid; Type 2 Diabetes; Obesity
4) By Sales Channel: Hospital Pharmacy; Retail Pharmacy; Online Provider
5) By Application: Oral; Parenteral
Subsegments:
1) By Solid: Tablets; Capsules; Other Solid Dosage Forms
2) By Liquid: Oral Solutions; Syrups; Injectable Solutions; Other Liquid Dosage Forms
Companies Mentioned: NGM Biopharmaceuticals Inc.; Novartis AG; AstraZeneca plc.; GlaxoSmithKline plc.; F. Hoffmann-La Roche AG; The Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Novo Nordisk A/S; Genfit SA; Intercept Pharmaceuticals Inc.; Enanta Pharmaceuticals Inc.; Blade Therapeutics Inc.; Galmed Pharmaceuticals Inc.; Immuron Limited; Terns Pharmaceuticals Inc.; Tobira Therapeutics Inc.; Arena Pharmaceuticals Inc.; Galectin Therapeutics Inc.; Viking Therapeutics; Madrigal Pharmaceuticals Inc.; Cirius Therapeutics; Akero Therapeutics Inc.; Echosens
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH4MNASN01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Non-Alcoholic Steatohepatitis (NASH) Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Non-Alcoholic Steatohepatitis (NASH) Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Non-Alcoholic Steatohepatitis (NASH) Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Non-Alcoholic Steatohepatitis (NASH) Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.3 Artificial Intelligence & Autonomous Intelligence
- 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
- 4.1.5 Industry 4.0 & Intelligent Manufacturing
4.2. Major Trends
- 4.2.1 Rising Prevalence Of Obesity And Type 2 Diabetes
- 4.2.2 Development Of Non-Invasive Diagnostic Tools
- 4.2.3 Increasing Research In Liver Fibrosis Therapies
- 4.2.4 Growth In Personalized And Targeted Drug Treatments
- 4.2.5 Expansion Of Hospital And Retail Pharmacy Networks

5. Non-Alcoholic Steatohepatitis (NASH) Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Specialty Clinics
5.3 Diagnostic Centers
5.4 Retail Pharmacies
5.5 Online Pharmacies

6. Non-Alcoholic Steatohepatitis (NASH) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Non-Alcoholic Steatohepatitis (NASH) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Non-Alcoholic Steatohepatitis (NASH) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Non-Alcoholic Steatohepatitis (NASH) Market Size, Comparisons And Growth Rate Analysis
7.3. Global Non-Alcoholic Steatohepatitis (NASH) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Non-Alcoholic Steatohepatitis (NASH) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Non-Alcoholic Steatohepatitis (NASH) Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

9.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Solid, Liquid
9.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
9.3. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
9.4. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital Pharmacy, Retail Pharmacy, Online Provider
9.5. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral, Parenteral
9.6. Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Solid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Tablets, Capsules, Other Solid Dosage Forms
9.7. Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Liquid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

10. Non-Alcoholic Steatohepatitis (NASH) Market Regional And Country Analysis

10.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market

11.1. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Non-Alcoholic Steatohepatitis (NASH) Market

12.1. China Non-Alcoholic Steatohepatitis (NASH) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Non-Alcoholic Steatohepatitis (NASH) Market

13.1. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Non-Alcoholic Steatohepatitis (NASH) Market

14.1. Japan Non-Alcoholic Steatohepatitis (NASH) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Non-Alcoholic Steatohepatitis (NASH) Market

15.1. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market

16.1. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Non-Alcoholic Steatohepatitis (NASH) Market

17.1. South Korea Non-Alcoholic Steatohepatitis (NASH) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Non-Alcoholic Steatohepatitis (NASH) Market

18.1. Taiwan Non-Alcoholic Steatohepatitis (NASH) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Non-Alcoholic Steatohepatitis (NASH) Market

19.1. South East Asia Non-Alcoholic Steatohepatitis (NASH) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market

20.1. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Non-Alcoholic Steatohepatitis (NASH) Market

21.1. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Non-Alcoholic Steatohepatitis (NASH) Market

22.1. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Non-Alcoholic Steatohepatitis (NASH) Market

23.1. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Non-Alcoholic Steatohepatitis (NASH) Market

24.1. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Non-Alcoholic Steatohepatitis (NASH) Market

25.1. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market

26.1. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Non-Alcoholic Steatohepatitis (NASH) Market

27.1. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Non-Alcoholic Steatohepatitis (NASH) Market

28.1. North America Non-Alcoholic Steatohepatitis (NASH) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Non-Alcoholic Steatohepatitis (NASH) Market

29.1. USA Non-Alcoholic Steatohepatitis (NASH) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Non-Alcoholic Steatohepatitis (NASH) Market

30.1. Canada Non-Alcoholic Steatohepatitis (NASH) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Non-Alcoholic Steatohepatitis (NASH) Market

31.1. South America Non-Alcoholic Steatohepatitis (NASH) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Non-Alcoholic Steatohepatitis (NASH) Market

32.1. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Non-Alcoholic Steatohepatitis (NASH) Market

33.1. Middle East Non-Alcoholic Steatohepatitis (NASH) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Non-Alcoholic Steatohepatitis (NASH) Market

34.1. Africa Non-Alcoholic Steatohepatitis (NASH) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Non-Alcoholic Steatohepatitis (NASH) Market Regulatory and Investment Landscape

36. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape And Company Profiles

36.1. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Non-Alcoholic Steatohepatitis (NASH) Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Non-Alcoholic Steatohepatitis (NASH) Market Company Profiles
- 36.3.1. NGM Biopharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. AstraZeneca plc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. GlaxoSmithKline plc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

37. Non-Alcoholic Steatohepatitis (NASH) Market Other Major And Innovative Companies

The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc.

38. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market

40. Non-Alcoholic Steatohepatitis (NASH) Market High Potential Countries, Segments and Strategies

40.1 Non-Alcoholic Steatohepatitis (NASH) Market In 2030 - Countries Offering Most New Opportunities
40.2 Non-Alcoholic Steatohepatitis (NASH) Market In 2030 - Segments Offering Most New Opportunities
40.3 Non-Alcoholic Steatohepatitis (NASH) Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer